REGN Deadline: Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (
NASDAQREGN) between November 2, 2023 and October 30, 2024. Regeneron describes itself as a “biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.”
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AADFive times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch
Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz reminds investors of the upcoming March 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (
NASDAQREGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”).
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron PharmaceuticalsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
DEADLINE NEXT WEEK: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Contact the Firm Before March 10, 2025PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or the “Company”) (
NASDAQREGN) on behalf of purchasers of Regeneron securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”).
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple MyelomaTARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (
NASDAQREGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. The European Commission is expected to announce a final decision in the coming months.
REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (
NASDAQREGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025
Regeneron Announces Investor Conference PresentationsTARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (
NASDAQREGN) will webcast management participation as follows:
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis MeetingEYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing IntervalsAt three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron PharmaceuticalsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 BillionTARRYTOWN, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (
NASDAQREGN) today announced financial results for the fourth quarter and full year 2024 and provided a business update.
